CTRI/2022/09/046057已完成未知
An Open-Label, Randomized, Single Oral Dose, Two-Period, Cross-Over Trial to Assess the Bioequivalence of Dydrogesterone 10mg tablets (Test Drug) of Medethix Inc. in Comparison with Tab. Duphaston (Dydrogesterone) 10mg tablets (Reference Drug) of Abbott Labs. in Healthy FemaleSubjects Under Fasting Conditions.
Medethix Inc0 个研究点目标入组 28 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1)Volunteers with age of 18 to 45 years old, both inclusive.
- •2)Non-pregnant, non-lactating female.
- •a.Female of childbearing potential must have a negative serum beta human chorionic gonadotropin pregnancy test performed within 28 days prior to first dosing day & prior to check-in of each period. They must be using an acceptable form of contraception.
- •b.For female of childbearing potential, acceptable forms of contraception include any one of the following:
- •Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study
- •Barrier methods containing or used in conjunction with a spermicidal agent
- •Surgical sterilization
- •Practicing sexual abstinence throughout the course of the study.
- •Female will not be considered of childbearing potential if one of the following is reported and documented on the medical history:
- •Postmenopausal with spontaneous amenorrhea for at least one year, or
- •Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or
- •Total hysterectomy and an absence of bleeding for at least 3 months.
- •18.5 to 30.0 weight in kg /m2, both inclusive
- •Able to communicate effectively with study personnel.
- •Able to give written informed consent to participate in the study.
- •All volunteers must be judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication which will include:
- •A physical examination with no clinically significant finding.
- •Results within normal limits or clinically non-significant for the following tests: Hematology, Blood Chemistry, Urinalysis, Immunological Tests, Serum (β-HCG) Pregnancy Test (for female of child bearing potential)
- •Additional tests and/or examinations may be performed, if necessary, based on Principal Investigator discretion.
排除标准
- •1) History of allergic responses to Dydrogesterone or other related drugs, or any of its formulation ingredients.
- •2) Known or suspected progestogen dependant neoplasms
- •3) Volunteer with undiagnosed irregular vaginal bleeding.
- •4) Volunteer with hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •5) Have significant diseases or clinically significant abnormal findings during screening
- •6) Any disease or condition like diabetes, psychosis, adrenal insufficiency, thyrotoxicosis, seizures or others which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, endocrine or any other body system.
- •7) Use of any hormone replacement therapy within 3 months prior to the first dose of study medication.
- •8) Use of enzyme-modifying drugs within 30 days prior to the first dose of study medication.
- •9) Use of estrogens 30 days prior to the first dose of study medication and throughout the study.
- •10) History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
- •11) Smokers who smoke 10 or more cigarettes per day or 20 or more biddies per day or those who cannot refrain from smoking during the study period.
- •12) History of difficulty with donating blood or difficulty in accessibility of veins.
- •13) A positive hepatitis screen (includes subtypes B and C).
- •14) A positive test result for HV antibody and/ or syphilis (RPR/VDRL).
- •15) Volunteers who have received a known investigational drug within ten elimination half-life of the administered drug prior to the first dose of study medication or have donated blood or loss of blood 50 mL to 100 mL within 30 days or 101 mL to 200 mL within 60 days or >200 mL within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever is greater.
- •16) History of difficulty in swallowing or of any gastrointestinal disease which could affect drug absorption.
- •17) Intolerance to venipuncture.
- •18) Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Sub-Investigator, could contraindicate the volunteer participation in this study.
研究者
相似试验
进行中（未招募）
不适用
A clinical trial to evaluate the effects of food on the bioavailability of CKD-397 in healthy male subjectsDiseases of The genitoruinary systemKCT0001862Chong Kun Dang16
已完成
不适用
A clinical trial to compare safety and pharmacokinetic characteristics of CKD-337KCT0001787Chong Kun Dang48
已完成
Unknown
Phase 1 Trial to Evaluate the pharmacokinetic characteristics and safety/tolerability of coadministration (AD-2071 and AD-2072) or fixed-dose combination(AD-207) in healthy adult volunteersDiseases of the circulatory systemKCT0009354Addpharma56
尚未招募
1 期
An Open Label, Randomized, Two-Period, Single Oral Dose, Crossover BE Study of SITAGAVIA (100 mg) of the GPO, Thailand with Januvia of ORGANON PHARMA (UK) LIMITED, United Kingdom in Normal, Healthy, Adult Human Subjects under Fasting ConditionsHealthy male and female subjectsBioequivalence fed conditionsTCTR20231101008The Government Pharmaceutical Organization30
尚未招募
1 期
An Open Label, Randomized, Two-Period, Single Oral Dose, Crossover Bioequivalence Study of RIBAROX (20 mg) (Rivaroxaban 20 mg tablets) of the GPO, Thailand with Xarelto (Rivaroxaban 20 mg tablets) of Bayer AG, Germany in Healthy, Adult Human Subjects under Fed ConditionsHealthy male and female subjectsBioequivalence fed conditionsTCTR20220804009The Government Pharmaceutical Organization32